Stathmin

A ubiquitous phosphoprotein that serves as an intracellular substrate for a variety of SIGNAL TRANSDUCTION PATHWAYS. PHOSPHORYLATION of stathmin occurs during CELL CYCLE progression, and stathmin functions as a microtubule-destabilizing protein that promotes MICROTUBULE depolymerization during INTERPHASE and late MITOSIS. Stathmin is expressed at very high levels in a variety of human CANCERS.

Also Known As:

Networked: 264 relevant articles (11 outcomes, 37 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Lin, Fang: 7 articles (07/2014 - 05/2004)
2.	Belletti, Barbara: 6 articles (01/2014 - 01/2005)
3.	Baldassarre, Gustavo: 6 articles (01/2014 - 01/2005)
4.	Wang, Xi: 5 articles (07/2014 - 11/2007)
5.	Wik, Elisabeth: 5 articles (01/2014 - 10/2010)
6.	Canzonieri, Vincenzo: 5 articles (01/2014 - 01/2005)
7.	Wang, Feng: 5 articles (01/2014 - 03/2008)
8.	Trovik, Jone: 5 articles (01/2014 - 10/2010)
9.	Colombatti, Alfonso: 5 articles (01/2014 - 01/2005)
10.	Zhang, Hui-Zhong: 5 articles (09/2010 - 05/2004)

Related Diseases

1.	Neoplasms (Cancer) 08/01/2014 - "A PubMed search using such terms as "stathmin", "microtubule dynamics", "epithelial-mesenchymal transition", "EMT", "malignant potential" and "cancer" was performed to identify relevant studies published in English. " 10/01/2013 - "Recently, stathmin 1 has been proposed to function as an oncogene based on some relevant studies in multiple types of human cancers. " 11/01/2011 - "Many studies suggest that high stathmin expression levels in cancer negatively influence the response to microtubule-targeting drugs. " 11/01/2008 - "In addition, through a combination of proteomics and immunological methods, this study demonstrates that stathmin 1alpha, a cytoskeletal protein implicated in tumor progression, undergoes a basic isoelectric point shift (p I) following uPAR suppression, suggesting that post-translational modification of stathmin occur secondary to uPAR suppression. " 01/01/2015 - "Stathmin in pancreatic neuroendocrine neoplasms: a marker of proliferation and PI3K signaling."
2.	Endometrial Neoplasms (Endometrial Cancer) 10/01/2010 - "Stathmin is superior to AKT and phospho-AKT staining for the detection of phosphoinositide 3-kinase activation and aggressive endometrial cancer." 05/01/2013 - "High Stathmin expression has recently been associated with clinical progress in endometrial cancers. " 05/15/2011 - "Overexpression of the oncogen Stathmin has been linked to aggressive endometrial carcinoma and a potential for PI3Kinase inhibitors in this disease. " 01/01/2014 - "Stathmin is a prognostic marker in many cancers, including endometrial cancer. " 05/15/2011 - "Stathmin immunohistochemical staining identifies endometrial carcinomas with lymph node metastases and poor survival. "
3.	Breast Neoplasms (Breast Cancer) 05/01/2007 - "Therefore, these data suggest a novel approach to improving the efficacy of certain antimicrotubule agents against breast cancer by regulating the function of stathmin." 05/01/2013 - "These studies provide the proof-of-principle that stathmin provides an attractive molecular target, which could serve as a primary focus of novel approaches to breast cancer." 05/01/2010 - "In a study of breast cancer cell lines(1) proposed that stathmin is required for survival of cells lacking p53, but this hypothesis was not tested directly. " 12/01/2015 - "Quantitative polymerase chain reaction and immunofluorescence by microscopic analysis of chimeras in vitro exhibited silencing of stathmin and survivin in the RB and breast cancer model. " 09/08/2015 - "Stathmin and phospho-stathmin protein signature is associated with survival outcomes of breast cancer patients."
4.	Stomach Neoplasms (Stomach Cancer) 10/01/2013 - "The aim of this study was to investigate the expression of stathmin 1 as well as its association with overall survival of gastric cancer patients. " 01/01/2015 - "Stathmin might be a potential molecular marker and target for the treatment of gastric cancer." 01/01/2015 - "Stathmin expression provides evidence for the treatment planning for gastric cancers. " 01/01/2015 - "Our results showed that the expression of stathmin was elevated in gastric cancer tissues, indicating a possible association between the stathmin expression and the disease occurrence. " 01/01/2015 - "Stathmin ASODN was transfected into gastric cancer SGC 7901 cell lines. "
5.	Inflammation 06/15/2010 - "Colocalization of stathmin with TLR3 on astrocytes, microglia, and neurons in multiple sclerosis-affected human brain indicates that as an endogenous TLR3 agonist, stathmin may fulfill previously unsuspected regulatory roles during inflammation and repair in the adult CNS." 01/01/2015 - "Expression of stathmin phosphorylation-deficient mutant abolished ANP protective effects against PepG-induced inflammation and EC permeability. " 06/01/2015 - "Also, heat-induced overproduction of proinflammatory cytokines might be associated with downregulation of stathmin 1. Heat-induced hypothalamic ischemia, apoptosis, injury (or upregulation of L-lactate dehydrogenase), blood-brain-barrier disruption (or upregulation of glial fibrillary acidic protein), oxidative stress (or upregulation of cytosolic dehydrogenase-1), and activated inflammation (or downregulation of stathmin 1) were all significantly reversed by whole body cooling. "

Related Drugs and Biologics

1.	Paclitaxel (Taxol)
2.	Small Interfering RNA (siRNA)
3.	docetaxel (Taxotere)
4.	Atrial Natriuretic Factor (ANF)
5.	Tubulin
6.	Messenger RNA (mRNA)
7.	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)
8.	Proteins (Proteins, Gene)
9.	Carrier Proteins (Binding Protein)
10.	Complementary DNA (cDNA)

Related Therapies and Procedures

1.	Drug Therapy (Chemotherapy)
2.	Heterologous Transplantation (Xenotransplantation)
3.	Axotomy
4.	Lasers (Laser)
5.	Hysterectomy